BNIPL antibody
Principal name
BNIPL antibody
Alternative names for BNIPL antibody
Bcl-2/adenovirus E1B 19 kDa-interacting protein 2-like protein
Gene ID
149428 (BNIPL)
Ncbi ID
Available reactivities
Available hosts
Available applications
Western blot / Immunoblot (WB), ELISA (detection) (E(detection)), Enzyme Immunoassay (E)
Background of BNIPL antibody
- Kit Component:
- - KN206811G1, BNIPL gRNA vector 1 in pCas-Guide vector
- KN206811G2, BNIPL gRNA vector 2 in pCas-Guide vector
- KN206811D, donor vector containing left and right homologous arms and Luciferase-Puro functional cassette
- GE100003, scramble sequence in pCas-Guide vector - CRISPR Manual:
- CRISPR/CAS9 Genome Editing Manual
Human OVCAR-3; WB Suggested Anti-BNIPL Antibody Titration: 0.2-1 ug/ml. Positive Control: OVCAR-3 cell lysate; BNIPL antibody - middle region (ARP52577_P050) in Human OVCAR-3 cells using Western Blot
Western Blot analysis of BNIPL expression in transfected 293T cell line (H00149428-T02) by BNIPL MaxPab polyclonal antibody.Lane 1: BNIPL transfected lysate(30.25 KDa).Lane 2: Non-transfected lysate.
Western Blot analysis of BNIPL expression in transfected 293T cell line (H00149428-T03) by BNIPL MaxPab polyclonal antibody.Lane 1: BNIPL transfected lysate(31.00 KDa).Lane 2: Non-transfected lysate.
WB Suggested Anti-BNIPL Antibody Titration: 0.2-1 ug/ml; Positive Control: OVCAR-3 cell lysate
Proteins & Growth Factors
| Catalog No. | Species | Pres. | Purity | Source | |
|---|---|---|---|---|---|
| TP306811 | BNIPL |
||||
| Recombinant protein of human BCL2/adenovirus E1B 19kD interacting protein like (BNIPL) | |||||
 |
Human | > 80 % Preparation: Recombint protein was captured through anti-DDK affinity column followed by conventiol chromatography steps. Purity Detail: > 80% as determined by SDS-PAGE and Coomassie blue staining. |
HEK293 cells |
20 µg /
€748.00
|
|
| OriGene Technologies, Inc. | |||||
Lysates
| Catalog No. | ||
|---|---|---|
| LY408738 | BNIPL overexpression lysate |
|
 |
0.1 mg /
€295.00
|
|
| OriGene Technologies, Inc. |